Preferred Label : Ozuriftamab Vedotin;
NCIt synonyms : Conditionally Active Biologic Anti-ROR2 Antibody-drug Conjugate; Anti-ROR2 CAB ADC; CAB Anti-ROR2 ADC BA3021; CAB-ROR2-ADC; Antibody-drug Conjugate BA3021; ROR2-targeted ADC BA3021; ADC BA3021; CAB-ROR2-ADC BA3021;
NCIt definition : An antibody-drug conjugate (ADC) composed of ozuriftamab, a conditionally active biologic
(CAB) antibody against receptor tyrosine kinase-like orphan receptor 2 (ROR2) conjugated
to monomethyl auristatin E, with potential antineoplastic activity. Upon administration
of ozuriftamab vedotin, the anti-ROR2 antibody becomes activated through an as of
yet not fully elucidated process, only under the unique microphysical conditions that
are present in the tumor microenvironment (TME) as a result of the glycolytic metabolism
of cancer cells and not in the microenvironment of normal, healthy tissues. Upon binding
to ROR2-expressing cancer cells and internalization, the cytotoxic agent kills the
cancer cells. ROR2, highly expressed during embryonic development while only minimally
expressed on certain normal, healthy cells, is involved in Wnt signal transduction
and is overexpressed on certain cancer cells. It plays a key role in cancer cell proliferation,
migration and invasion. High levels of ROR2 expression often correlates with poor
prognosis. The CAB antibody allows for efficient binding to ROR2-expressing cancer
cells only, thereby maximizing efficacy while minimizing toxicity by avoiding activation
and thus binding of the antibody to normal, healthy ROR2-expressing cells under normal
conditions.;
UNII : BPM6YN0KLI;
CAS number : 2460400-11-5;
Molecule name : BA 3021; BA3021;
NCI Metathesaurus CUI : CL556342;
Origin ID : C155812;
UMLS CUI : C5575127;
Currated CISMeF NLP mapping
- Semantic type(s)
- concept_is_in_subset
- has_target
